Published in Hum Gene Ther on February 01, 2008
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov (2010) 4.25
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest (2009) 2.13
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater (2010) 1.50
Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol (2016) 1.40
Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res (2011) 1.35
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release (2014) 1.32
Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci U S A (2009) 1.28
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol (2010) 1.20
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun (2014) 1.19
Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA (2009) 1.16
Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res (2009) 1.11
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
Clinical status of duplex RNA. Bioorg Med Chem Lett (2010) 1.04
Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res (2010) 1.03
Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA (2009) 1.02
In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano (2011) 0.99
Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol (2009) 0.98
Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res (2010) 0.97
Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. Mol Ther (2010) 0.95
Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles. Int J Mol Sci (2013) 0.95
Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther (2011) 0.92
Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res (2014) 0.90
Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I. Mol Ther (2013) 0.88
Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene. Br J Cancer (2013) 0.88
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
Identification of RNase L-dependent, 3'-end-modified, viral small RNAs in Sindbis virus-infected mammalian cells. MBio (2013) 0.84
Pseudovirions as vehicles for the delivery of siRNA. Pharm Res (2009) 0.84
Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy. J Virol (2014) 0.84
Adenosine modification may be preferred for reducing siRNA immune stimulation. Nucleic Acid Ther (2012) 0.83
Personalized cancer approach: using RNA interference technology. World J Surg (2011) 0.83
AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i. Gene Ther (2011) 0.82
Technologies for controlled, local delivery of siRNA. J Control Release (2015) 0.80
siRNA for Influenza Therapy. Viruses (2010) 0.80
Lentiviral vector-mediated RNA silencing in the central nervous system. Hum Gene Ther Methods (2013) 0.79
A simple Bayesian estimate of direct RNAi gene regulation events from differential gene expression profiles. BMC Genomics (2011) 0.79
Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers. J Biol Eng (2012) 0.78
Base modification strategies to modulate immune stimulation by an siRNA. Chembiochem (2014) 0.78
Buffering capacity and size of siRNA polyplexes influence cytokine levels. Mol Ther (2012) 0.78
Magnetic Nanoparticle Based Nonviral MicroRNA Delivery into Freshly Isolated CD105(+) hMSCs. Stem Cells Int (2014) 0.78
Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice. Mol Ther Nucleic Acids (2013) 0.78
MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy. Mini Rev Med Chem (2015) 0.77
Gene silencing below the immune radar. J Clin Invest (2009) 0.77
siRNA Delivery from an Injectable Scaffold for Wound Therapy. Adv Wound Care (New Rochelle) (2013) 0.77
Deficiency in either 4E-BP1 or 4E-BP2 augments innate antiviral immune responses. PLoS One (2014) 0.75
Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model. J Huntingtons Dis (2015) 0.75
Microporation is an efficient method for siRNA-induced knockdown of PEX5 in HepG2 cells: evaluation of the transfection efficiency, the PEX5 mRNA and protein levels and induction of peroxisomal deficiency. Histochem Cell Biol (2014) 0.75
Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing. Mol Ther Methods Clin Dev (2017) 0.75
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther (2005) 3.28
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release (2005) 2.47
siRNA and innate immunity. Oligonucleotides (2009) 2.28
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest (2009) 2.13
Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther (2008) 2.06
2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 1.85
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res (2005) 1.83
Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Control Release (2006) 1.23
Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J Infect Dis (2013) 1.12
Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. Mol Ther (2007) 0.99
Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids. Biochim Biophys Acta (2003) 0.87
Factors limiting autogene-based cytoplasmic expression systems. FASEB J (2005) 0.87
Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol (2002) 0.86
Analysis of differential lipofection efficiency in primary and established myoblasts. Mol Ther (2002) 0.84
I too was assimilated to band six - so i decided to retire. Nurs Stand (2006) 0.75